The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 18, 2017

Filed:

Jun. 30, 2015
Applicant:

Jazz Pharmaceuticals International Limited, Hamilton, BM;

Inventors:

David J. Ellis, Los Altos, CA (US);

George P. Miljanich, Redwood City, CA (US);

David E. Shields, San Lorenzo, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/00 (2006.01); A61K 31/137 (2006.01); A61K 31/451 (2006.01); C07K 14/435 (2006.01); A61K 38/17 (2006.01); A61K 31/195 (2006.01); A61K 31/4168 (2006.01); A61K 31/445 (2006.01); A61K 31/4468 (2006.01); A61K 31/4535 (2006.01); A61K 31/485 (2006.01); A61K 45/06 (2006.01); A61K 47/12 (2006.01); A61K 47/18 (2017.01);
U.S. Cl.
CPC ...
A61K 38/1767 (2013.01); A61K 9/0085 (2013.01); A61K 31/137 (2013.01); A61K 31/195 (2013.01); A61K 31/4168 (2013.01); A61K 31/445 (2013.01); A61K 31/4468 (2013.01); A61K 31/451 (2013.01); A61K 31/4535 (2013.01); A61K 31/485 (2013.01); A61K 38/17 (2013.01); A61K 45/06 (2013.01); A61K 47/12 (2013.01); A61K 47/183 (2013.01); C07K 14/43504 (2013.01);
Abstract

The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl 1, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ω-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.


Find Patent Forward Citations

Loading…